Future Roles of Lapatinib in ErbB2-Positive Breast Cancer: Adjuvant and Neoadjuvant Trials

Breast care

Christoph Thomssen¹  Serban-Dan Costa¹  Christian Jackisch¹ 

[1] aDepartment of Obstetrics, Universitätsfrauenklinik Magdeburg, Halle/Saale, Germany

关键词: Lapatinib;    ErbB2-positive breast cancer;    Adjuvant;    Neoadjuvant;    ALTTO study;    TEACH study;   

DOI  :  10.1159/000285778

学科分类：泌尿医学

来源: S Karger AG

【 摘 要 】

Lapatinib is potentially an ideal therapy for the adjuvant and neoadjuvant treatment of women with breast cancer due to its convenience of use (oral, once-daily administration) and because it has shown activity in the first-line and refractory metastatic settings. Furthermore, the dual tyrosine kinase inhibitor appears to have a low incidence of cardiotoxicity, and may decrease the rate of later brain metastases. Therefore, several cooperative groups and academic centers have initiated trials investigating lapatinib in the treatment of early-stage ErbB2 (HER2)-overexpressing breast cancer.

【 授权许可】

Unknown